SAB Biotherapeutics, Inc. — Director's Dealing 2021

Oct 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Big Cypress Acquisition Corp. (BCYP)
CIK: 0001833214
Period of Report: 2021-10-14

Reporting Person: Reich Samuel J (Director, CEO and CFO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-14	Common Stock	P	1000	$10.11	Acquired	1000	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3047825	Indirect

Footnotes

F1: Represents 1,000 shares of the issuer's common stock acquired jointly by the reporting person and the reporting person's spouse in open market transactions.

F2: Includes 3,047,825 shares of the issuer's common stock held directly by Big Cypress Holdings LLC (the "Sponsor") and indirectly by Samuel J. Reich and Ilan Katz as managers of the Sponsor, which includes 417,200 private placement units of the issuer. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of common stock of the issuer and one-half of one warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering.